Agonists vs levodopa in PD: The thrilla of whitha

Neurology

Volumn 60, Issue 3, 2003, Pages 360-362

  Wooten, G F ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; APOMORPHINE; BROMOCRIPTINE; CATECHOL METHYLTRANSFERASE; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG METABOLITE; ERGOT DERIVATIVE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; RADIOLIGAND; ROPINIROLE;

BEHAVIOR DISORDER; CELL SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DYSKINESIA; EDITORIAL; ERYTHROMELALGIA; HALLUCINATION; HISTORY OF MEDICINE; HUMAN; KIDNEY FAILURE; LEG EDEMA; LIFE EXPECTANCY; MENTAL DISEASE; NAUSEA; NERVE CELL; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERITONEAL DISEASE; PLEURAL FIBROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RAYNAUD PHENOMENON; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMNOLENCE; TREATMENT OUTCOME;

EID: 0037432003     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.60.3.360     Document Type: Editorial

References (12)

1. Cotzias GC, Papavasiliou PS, Fehling C, et al. Similarities between neurologic effects of L-dopa and apomorphine. N Engl J Med 1970;282: 31-33.
2. Ahlskog JE. Medical treatment of later-stage motor problems of Parkinson's disease. Mayo Clin Proc 1999;74:1239-1254.
3. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
4. Rascol O, Brooks D, Korczyn A, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491.
5. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
6. Whore AL, Renny P, Davis MR, et al. The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with L-dopa. Neurology 2002;58:A82-A83.
7. Albin RA, Frey KA. Initial agonist treatment of Parkinson disease: a critique. Neurology 2003;60:390-394.
8. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003;60:381-389.
9. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa controlled study. OSG Study Group. Movement Disorders 1998;13:39-45.
10. Trugman JM, James CL, Wooten GF. D1/D2 dopamine receptor stimulation by L-dopa: a [14C]-2-deoxyglucose autoradiographic study. Brain 1991;114:1429-1440.
11. Chase T, Baronti F, Fabbrini G, et al. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 1989;39:7-10.
12. Wooten GF. Anatomy and function of dopamine receptors: understanding pathophysiology of fluctuations in Parkinson's disease. Parkinsonism Relat Disord 2001;8:79-83.